ATAI Life Sciences N.V (NASDAQ: ATAI) kicked off on Monday, up 6.16% from the previous trading day, before settling in for the closing price of $2.11. Over the past 52 weeks, ATAI has traded in a range of $1.03-$2.64.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
While this was happening, its average annual earnings per share was recorded 43.32%. With a float of $137.08 million, this company’s outstanding shares have now reached $199.78 million.
In an organization with 54 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 87.92%, operating margin of -5312.18%, and the pretax margin is -8014.28%.
ATAI Life Sciences N.V (ATAI) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of ATAI Life Sciences N.V is 31.72%, while institutional ownership is 9.93%. The most recent insider transaction that took place on Jun 04 ’25, was worth 198,408. Before that another transaction happened on Mar 21 ’25, when Company’s Chief Business Officer sold 48,563 for $1.35, making the entire transaction worth $65,560. This insider now owns 115,636 shares in total.
ATAI Life Sciences N.V (ATAI) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.1 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 43.32% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 29.49% during the next five years compared to 18.62% growth over the previous five years of trading.
ATAI Life Sciences N.V (NASDAQ: ATAI) Trading Performance Indicators
Take a look at ATAI Life Sciences N.V’s (ATAI) current performance indicators. Last quarter, stock had a quick ratio of 4.07. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1362.70.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.80, a number that is poised to hit -0.13 in the next quarter and is forecasted to reach -0.57 in one year’s time.
Technical Analysis of ATAI Life Sciences N.V (ATAI)
Let’s dig in a bit further. During the last 5-days, its volume was 1.82 million. That was inferior than the volume of 2.53 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 16.72%. Additionally, its Average True Range was 0.17.
During the past 100 days, ATAI Life Sciences N.V’s (ATAI) raw stochastic average was set at 73.15%, which indicates a significant increase from 31.03% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 64.01% in the past 14 days, which was lower than the 102.27% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.74, while its 200-day Moving Average is $1.53. However, in the short run, ATAI Life Sciences N.V’s stock first resistance to watch stands at $2.29. Second resistance stands at $2.33. The third major resistance level sits at $2.42. If the price goes on to break the first support level at $2.16, it is likely to go to the next support level at $2.07. Assuming the price breaks the second support level, the third support level stands at $2.03.
ATAI Life Sciences N.V (NASDAQ: ATAI) Key Stats
The company with the Market Capitalisation of 449.69 million has total of 200,338K Shares Outstanding. Its annual sales at the moment are 310 K in contrast with the sum of -149,270 K annual income. Company’s last quarter sales were recorded 1,560 K and last quarter income was -26,430 K.